Related Experiment Videos
Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma
Massimo Offidani1, Laura Corvatta, Monica Marconi
1Clinic of Haematology, Polytechnic University of Marches, Ancona, Italy. m.offidani@ao-umbertoprimo.marche.it
Summary
Combining thalidomide with melphalan improved treatment response and progression-free survival for advanced multiple myeloma patients. This combination therapy showed enhanced efficacy without a significant increase in severe toxicity, offering a promising therapeutic option.
Area of Science:
- Hematology
- Clinical Oncology
- Pharmacology
Background:
- Thalidomide is a key agent for multiple myeloma (MM).
- Thalidomide demonstrates synergistic effects with other drugs.
- The combination of thalidomide with chemotherapy requires further investigation for MM treatment.
Purpose of the Study:
- To compare the efficacy and toxicity of thalidomide alone versus in combination with oral melphalan.
- To evaluate response rates, progression-free survival (PFS), and overall survival.
- To assess the safety profile of the combination therapy in advanced MM patients.
Main Methods:
- A prospective study comparing two groups of advanced MM patients.
- Group T (n=23) received escalating doses of oral thalidomide.
- Group TM (n=27) received oral thalidomide plus oral melphalan for four consecutive days monthly.
Main Results:
- The thalidomide-melphalan (TM) group showed significantly higher response rates (59% vs. 26%, P=0.009).
- Two-year PFS was significantly longer in the TM group (61% vs. 45%, P=0.0376).
- Toxicity was comparable, with no significant increase in severe adverse events, though DVT and grade 3 leukopenia were more frequent in the TM group.
Conclusions:
- Thalidomide combined with oral melphalan improves response rates and PFS in advanced MM.
- The combination therapy is well-tolerated, with manageable toxicity.
- This regimen represents a viable treatment option for patients with advanced multiple myeloma.